Trial Profile
A phase I pharmacokinetic study of erlotinib administration in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Dec 2015
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- 06 Dec 2015 New trial record